- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01419665
GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL) (ASSIST_FL)
April 22, 2021 updated by: Sandoz
A Randomized, Controlled, Double-Blind Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of GP2013 vs. MabThera® in Patients With Previously Untreated, Advanced Stage Follicular Lymphoma
The purpose of this study is to demonstrate comparability of the ORR in patients with previously untreated, advanced stage FL who receive GP2013-treatment to patients who receive MabThera-treatment.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
629
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
La Plata, Argentina
- Investigative Site
-
Rosario, Argentina
- Investigative Site
-
San Miguel de Tucuman, Argentina
- Investigative Site
-
-
-
-
-
Adelaide, Australia
- Investigative Site
-
Ballarat, Australia
- Investigative Site
-
Epping, Australia
- Investigative Site
-
Footscray, Australia
- Investigative Site
-
Wodonga, Australia
- Investigative Site
-
-
-
-
-
Graz, Austria
- Investigative Site
-
Wien, Austria
- Investigative Site
-
-
-
-
-
Barretos, Brazil
- Investigative Site
-
Barretos, Brazil
- Investigator site
-
Botucatu, Brazil
- Investigative Site
-
Campinas, Brazil
- Investigative Site
-
Curitiba, Brazil
- Investigative Site
-
Florianopolis, Brazil
- Investigative Site
-
Fortaleza, Brazil
- Investigative Site
-
Goiania, Brazil
- Investigative Site
-
Jau, Brazil
- Investigative Site
-
Passo Fundo, Brazil
- Investigative Site
-
Porto Alegre, Brazil
- Investigative Site
-
Rio de Janeiro, Brazil
- Investigative Site
-
Santo Andre, Brazil
- Investigative Site
-
Sao Paulo, Brazil
- Investigative Site
-
Sorocaba, Brazil
- Investigative Site
-
-
-
-
-
Pleven, Bulgaria
- Investigative Site
-
Plovdiv, Bulgaria
- Investigative Site
-
Ruse, Bulgaria
- Investigative Site
-
Sofia, Bulgaria
- Investigative Site
-
Varna, Bulgaria
- Investigative Site
-
-
-
-
-
Medellin, Colombia
- Investigative Site
-
Monteria, Colombia
- Investigative Site
-
-
-
-
-
Colmar, France
- Investigative Site
-
Nimes, France
- Investigative Site
-
Strasbourg, France
- Investigative Site
-
-
-
-
-
Bad Saarow, Germany
- Investigative Site
-
Koblenz, Germany
- Investigative Site
-
-
-
-
-
Athens, Greece
- Investigative Site
-
Ioannina, Greece
- Investigative Site
-
Larissa, Greece
- Investigative Site
-
Patras, Greece
- Investigative Site
-
-
-
-
-
Györ, Hungary
- Investigative Site
-
Kaposvar, Hungary
- Investigative Site
-
-
-
-
-
Ahmedabad, India
- Investigative Site
-
Amritsar, India
- India
-
Aurangabad, India
- Investigative Site
-
Bangalore, India
- Investigative Site
-
Chennai, India
- Investigative Site
-
Hyderabad, India
- Investigative Site
-
Kolkata, India
- Investigative Site
-
Kolkata, India
- Investigtive site
-
Madurai, India
- Investigative Site
-
Mumbai, India
- Investigative Site
-
Nashik, India
- Investigative Site
-
New Delhi, India
- Investigative Site
-
Pune, India
- Investigative Site
-
Surat, India
- Investigative Site
-
Trivandrum, India
- Investigative Site
-
Vellore, India
- Investigative Site
-
-
-
-
-
Dublin, Ireland
- Investigative Site
-
Limerick, Ireland
- Investigative Site
-
Waterford, Ireland
- Investigative Site
-
-
-
-
-
Ashkelon, Israel
- Investigative Site
-
Nahariya, Israel
- Investigative Site
-
-
-
-
-
Bari, Italy
- Investigative Site
-
Firenze, Italy
- Investigative Site
-
Meldola, Italy
- Investigative Site
-
Milano, Italy
- Investigative Site
-
Palermo, Italy
- Investigative Site
-
Pavia, Italy
- Investigative Site
-
Pescara, Italy
- Investigative Site
-
Piacenza, Italy
- Investigative Site
-
Ravenna, Italy
- Investigative Site
-
Reggio Calabria, Italy
- Investigative Site
-
Varese, Italy
- Investigative Site
-
-
-
-
-
Aomori, Japan
- Investigative Site
-
Fukuoka, Japan
- Investigative Site
-
Gifu, Japan
- Investigative Site
-
Kagoshima, Japan
- Investigative Site
-
Kitakyushu, Japan
- Investigative Site
-
Kobe, Japan
- Investigative Site
-
Komaki, Japan
- Investigative Site
-
Matsuyama, Japan
- Investigative Site
-
Ogaki, Japan
- Investigative Site
-
Okayama, Japan
- Investigative Site
-
Omura, Japan
- Invstigative site
-
Saga, Japan
- Investigative Site
-
Tachikawa, Japan
- Investigative Site
-
Ōtake, Japan
- Investigative Site
-
-
-
-
-
Alor Setar, Malaysia
- Investigative Site
-
Ampang, Malaysia
- Investigative Site
-
George Town, Malaysia
- Investigative Site
-
Ipoh, Malaysia
- Investigative Site
-
Johor Bahru, Malaysia
- Investigative Site
-
Klang, Malaysia
- Investigative Site
-
Kuala Lumpur, Malaysia
- Investigative Site
-
Kuching, Malaysia
- Investigative Site
-
Melaka, Malaysia
- Investigative Site
-
Pulau Pinang, Malaysia
- Investigative Site
-
Subang Jaya, Malaysia
- Investigative Site
-
-
-
-
-
Amsterdam, Netherlands
- Investigative Site
-
Delft, Netherlands
- Investigative Site
-
Gouda, Netherlands
- Investigative Site
-
Heerlen, Netherlands
- Investigative Site
-
Rotterdam, Netherlands
- Investigative Site
-
Schiedam, Netherlands
- Investigative Site
-
Sittard, Netherlands
- Investigative Site
-
Zwolle, Netherlands
- Investigative Site
-
-
-
-
-
Lima, Peru
- Investigative Site
-
-
-
-
-
Brzozow, Poland
- Investigative Site
-
Bydgoszcz, Poland
- Investigative Site
-
Chorzow, Poland
- Investigative Site
-
Krakow, Poland
- Investigative Site
-
Lublin, Poland
- Investigative Site
-
Warszawa, Poland
- Investigative Site
-
-
-
-
-
Braga, Portugal
- Investigative Site
-
Coimbra, Portugal
- Investigative Site
-
Lisboa, Portugal
- Investigative Site
-
Porto, Portugal
- Investigative Site
-
-
-
-
-
Brasov, Romania
- Investigative Site
-
Bucharest, Romania
- Investigative Site
-
Cluj-Napoca, Romania
- Investigative Site
-
Iasi, Romania
- Investigative Site
-
Timisoara, Romania
- Investigative Site
-
-
-
-
-
Arkhangelsk, Russian Federation
- Investigative Site
-
Chelyabinsk, Russian Federation
- Investigative Site
-
Krasnodar, Russian Federation
- Investigative Site
-
Kursk, Russian Federation
- Investigative Site
-
Moscow, Russian Federation
- Investigative Site
-
Nizhniy Novgorod, Russian Federation
- Investigative Site
-
Rostov-on -Don, Russian Federation
- Investigative Site
-
St. Petersburg, Russian Federation
- Investigative Site
-
-
-
-
-
Cape Town, South Africa
- Investigative Site
-
George, South Africa
- Investigative Site
-
Johannesburg, South Africa
- Investigative Site
-
Port Elizabeth, South Africa
- Investigative Site
-
Pretoria, South Africa
- Investigative Site
-
-
-
-
-
Barcelona, Spain
- Investigative Site
-
Madrid, Spain
- Investigative Site
-
Oviedo, Spain
- Investigative Site
-
San Sebastian, Spain
- Investigative Site
-
Sevilla, Spain
- Investigative Site
-
Zaragoza, Spain
- Investigative Site
-
-
-
-
-
Cherkasy, Ukraine
- Investigative Site
-
Dnipropetrovsk, Ukraine
- Investigative Site
-
Donetsk, Ukraine
- Investigative Site
-
Ivano-Frankivsk, Ukraine
- Investigative Site
-
Kharkiv, Ukraine
- Investigative Site
-
Kyiv, Ukraine
- Investigative Site
-
Lviv, Ukraine
- Investigative Site
-
-
-
-
-
Eastbourne, United Kingdom
- Investigative Site
-
London, United Kingdom
- Investigative Site
-
Worthing, United Kingdom
- Investigative Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient with previously untreated advanced stage, CD20-positive FL
- Patient with ECOG performance status 0, 1 or 2.
Exclusion Criteria:
- Patient with Grade 3b (aggressive) FL or any histology other than FL grade 1, 2 or 3a
- Patient who has previously received any prior therapy for lymphoma
- Patient with evidence of any uncontrolled, active infection (viral, bacterial or fungal).
- Patient with any malignancy within 5 years prior to date of randomization, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer.
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GP2013
Type: Biological/Vaccine
|
Type: Biological/Vaccine
Other Names:
|
Active Comparator: rituximab
Type: Biological/Vaccine
|
Type: Biological/Vaccine
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: 24 weeks
|
ORR is defined as the proportion of patients whose best overall disease response was either CR or PR during the combination treatment period based on blinded independent central radiology review.
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To Evaluate the Complete Response (CR) Rate During the Combination Treatment Period
Time Frame: 24 weeks
|
24 weeks
|
|
To Evaluate the Partial Response (PR) Rate During the Combination Treatment Period
Time Frame: 24 weeks
|
24 weeks
|
|
To Evaluate the Progression Free Survival (PFS) With up to 3 Years of Follow-up Post Randomization
Time Frame: 3 years
|
Number of participants with progression free survival events
|
3 years
|
To Evaluate the Overall Survival (OS) With up to 3 Years of Follow-up Post Randomization, as Assessed by the Number of Deaths
Time Frame: 3 years
|
OS was defined as the time from date of randomization to date of death due to any cause.
If a patient was not known to have died, OS was censored at the date of last contact including survival follow-up.
|
3 years
|
To Evaluate the Incidence of Immunogenicity (ADA Formation) Against GP2013 and MabThera (Rituximab)
Time Frame: 24 weeks, 3 years
|
number of participants with confirmed positive ADA
|
24 weeks, 3 years
|
To Evaluate a PK Marker Following the Treatment With GP2013-Chemotherapy and MabThera-Chemotherapy (C Max)
Time Frame: day 63
|
C max For descriptive purposes only, no hypothesis testing |
day 63
|
To Evaluate a PK Marker Following the Treatment With GP2013-Chemotherapy and MabThera-Chemotherapy (C Trough)
Time Frame: day 63
|
C through For descriptive purposes only, no hypothesis testing |
day 63
|
To Evaluate a PD Marker (Peripheral CD19+ B-cell Counts) Following the Treatment With GP2013 + Chemotherapy Amd MabThera- Chemotherapy
Time Frame: 21 days
|
AUEC (0-21d) For descriptive purposes only, no hypothesis testing |
21 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2011
Primary Completion (Actual)
July 10, 2015
Study Completion (Actual)
January 22, 2018
Study Registration Dates
First Submitted
August 17, 2011
First Submitted That Met QC Criteria
August 17, 2011
First Posted (Estimate)
August 18, 2011
Study Record Updates
Last Update Posted (Actual)
May 14, 2021
Last Update Submitted That Met QC Criteria
April 22, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, Follicular
- Physiological Effects of Drugs
- Antirheumatic Agents
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Rituximab
Other Study ID Numbers
- GP13-301
- 2010-019522-13 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Follicular Lymphoma
-
Joseph TuscanoNational Cancer Institute (NCI); Genentech, Inc.; Pharmacyclics LLC.RecruitingAnn Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
National Cancer Institute (NCI)TerminatedStage III Grade 1 Follicular Lymphoma | Stage III Grade 2 Follicular Lymphoma | Stage III Grade 3 Follicular Lymphoma | Stage IV Grade 1 Follicular Lymphoma | Stage IV Grade 2 Follicular Lymphoma | Stage IV Grade 3 Follicular LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterFox Chase Cancer Center; Pharmacyclics LLC.TerminatedFollicular Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade IIIaUnited States
-
Robert LowskyNational Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide FoundationCompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Olivia Newton-John Cancer Research InstituteBristol-Myers Squibb; Barwon Health; Austin Health; Eastern Health; Fiona Stanley... and other collaboratorsRecruitingFollicular Lymphoma Stage II | Follicular Lymphoma Stage III | Follicular Lymphoma Stage IVAustralia
-
Fondazione Italiana Linfomi ONLUSCompletedFollicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3AItaly
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGrade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...United States
-
National Cancer Institute (NCI)Celgene CorporationActive, not recruitingAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
Clinical Trials on GP2013
-
SandozNovartis PharmaceuticalsCompletedIndolent B-cell Non-Hodgkin's LymphomaJapan
-
SandozNovartis PharmaceuticalsCompletedRheumatoid ArthritisUnited States, Spain, Turkey, Argentina, Austria, Belgium, Brazil, Estonia, France, Germany, Hungary, India, Italy, Romania
-
SandozHexal AGCompletedRheumatoid ArthritisUnited States, Germany, Poland, Hungary